Disease relevance of temocapril hydrochloride

• The present study demonstrated that temocapril hydrochloride, an angiotensin converting enzyme inhibitor, decreases tumor tBF markedly in LY80 tumor, a subline of Yoshida sarcoma in the rat, without affecting the blood flow in liver, kidney, bone marrow, and brain [1].
• The pharmacokinetics of temocapril hydrochloride, a novel prodrug-type angiotensin-I converting enzyme (ACE) inhibitor, has been studied in patients with mild (Group II) to severe (Group III) renal insufficiency in comparison with subjects with normal renal function (Group I) [2].
• Effect of temocapril hydrochloride on serum lipid levels in patients with hypertensive type 2 diabetes mellitus [3].
• It is concluded that temocapril hydrochloride favorably affects the serum lipoprotein metabolism of hypertensive type 2 dependent diabetes mellitus patients [3].

High impact information on temocapril hydrochloride

• CGP-28392 (10(-6) M), a Ca2+ channel activator, induced a rhythmic activity superimposed on a gradual increase of [Ca2+]i and tension in SHR aortas but not in the aortas of CS-622-treated SHR or untreated WKY rats [4].
• When slightly depolarized in 10 or 12 mM K+ solution, the aortas from CS-622-treated SHR contracted in response to CGP-28392 [5].
• The aortic tone from the individual rats correlated well with systolic blood pressure in both CS-622-treated and control SHR [6].
• Long-term effects of a novel angiotensin converting enzyme (ACE) inhibitor, CS-622, on Ca2+-dependent tone in aortic smooth muscles of spontaneously hypertensive rats (SHR) were examined [6].
• We conclude that after prolonged administration CS-622 reduced the high vascular tension resulting from increased Ca2+ permeability of vascular smooth muscle membrane in SHR and that the restoration of normal Ca2+ permeability of vascular smooth muscles may underlie long-term antihypertensive action of ACE inhibitors [6].

Anatomical context of temocapril hydrochloride

• In Krebs-Henseleit solution, removal of Ca2+ caused much greater relaxation in aortas excised from control SHR than those from SHR treated with CS-622 [6].

Associations of temocapril hydrochloride with other chemical compounds

• The exaggerated myogenic tone in aortas of SHR was attenuated in the medium containing nicardipine but was not altered in the presence of CS-622 diacid (active form of CS-622) at a concentration high enough to fully inhibit aortic ACE [6].
• Determination of a new angiotensin-converting enzyme inhibitor (CS-622) and its active metabolite in plasma and urine by gas chromatography-mass spectrometry using negative ion chemical ionization [7].
• A simple and sensitive enzyme immunoassay (EIA) for determination of the active metabolite (RS-5139) of a new angiotensin converting enzyme inhibitor (CS-622) was developed [8].

Gene context of temocapril hydrochloride

• In Part II they took seven once daily oral tablet doses of 20 mg temocapril hydrochloride [9].

Analytical, diagnostic and therapeutic context of temocapril hydrochloride

• In normal K+ medium, a marked contraction was elicited by increasing Ca2+ concentration from 0 to 3 mM in aortas from a control group of SHR, but not in aortas from SHR treated with CS-622 [5].

References